SEELOS THERAPEUTICS INC's ticker is SEEL and the CUSIP is 81577F109. A total of 114 filers reported holding SEELOS THERAPEUTICS INC in Q3 2021. The put-call ratio across all filers is 0.35 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,612 | -82.3% | 155,500 | +14.8% | 0.00% | -100.0% |
| Q2 2023 | $161,923 | +72.9% | 135,500 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $93,658 | +1.8% | 135,500 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $92,000 | -34.3% | 135,500 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $140,000 | +52.2% | 135,500 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $92,000 | -19.3% | 135,500 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $114,000 | -66.8% | 135,500 | -35.6% | 0.00% | -50.0% |
| Q4 2021 | $343,000 | -44.9% | 210,500 | -18.6% | 0.00% | -50.0% |
| Q3 2021 | $623,000 | -13.7% | 258,500 | -5.5% | 0.00% | -33.3% |
| Q2 2021 | $722,000 | -40.3% | 273,500 | +12.8% | 0.01% | -45.5% |
| Q1 2021 | $1,210,000 | +460.2% | 242,500 | +77.0% | 0.01% | +450.0% |
| Q4 2020 | $216,000 | +980.0% | 137,000 | +585.0% | 0.00% | – |
| Q2 2020 | $20,000 | +100.0% | 20,000 | 0.0% | 0.00% | – |
| Q1 2020 | $10,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ACUTA CAPITAL PARTNERS, LLC | 2,500,000 | $4,075,000 | 1.71% |
| Connacht Asset Management LP | 498,925 | $813,000 | 0.79% |
| GENDELL JEFFREY L | 2,449,267 | $3,992,000 | 0.32% |
| MANGROVE PARTNERS IM, LLC | 2,133,436 | $3,478,000 | 0.21% |
| Uniplan Investment Counsel, Inc. | 1,550,359 | $2,527,000 | 0.14% |
| Financial Advocates Investment Management | 24,673 | $1,994,000 | 0.13% |
| Connacht Asset Management LP | 72,300 | $118,000 | 0.12% |
| Woodline Partners LP | 4,047,231 | $6,597,000 | 0.09% |
| 1492 Capital Management LLC | 108,286 | $177,000 | 0.09% |
| Ikarian Capital, LLC | 244,171 | $398,000 | 0.06% |